Details for New Drug Application (NDA): 201917

✉ Email this page to a colleague

NDA 201917 describes INCIVEK, which is a drug marketed by Vertex Pharms and is included in one NDA. There are two patents protecting this drug. Additional details are available on the INCIVEK profile page.

The generic ingredient in INCIVEK is telaprevir. There are three drug master file entries for this compound. Additional details are available on the telaprevir profile page.

Summary for 201917

Tradename:	INCIVEK
Applicant:	Vertex Pharms
Ingredient:	telaprevir
Patents:	2

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 201917

Generic Entry Date for 201917^: ⤷ Subscribe* Constraining patent/regulatory exclusivity: ⤷ Subscribe Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	375MG
Approval Date:	May 23, 2011	TE:		RLD:	No
Patent:	⤷ Subscribe	Patent Expiration:	Feb 25, 2025	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patent:	⤷ Subscribe	Patent Expiration:	May 30, 2028	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	METHOD OF TREATING CHRONIC HEPATITIS C

Expired US Patents for NDA 201917

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011	⤷ Subscribe	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for 201917

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 201917

Profile for product number 001

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 201917